European regulatory authority adopts a positive opinion for an update of the Wegovy® label to reflect risk reduction of major adverse cardiovascular events
July 25, 2024 11:08 ET
|
Novo Nordisk A/S
Bagsværd, Denmark, 25 July 2024 – Novo Nordisk today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for an...
Novo Nordisk A/S - share repurchase programme
July 22, 2024 08:22 ET
|
Novo Nordisk A/S
Bagsværd, Denmark, 22 July 2024 – On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16...
Novo Nordisk A/S - share repurchase programme
July 15, 2024 06:50 ET
|
Novo Nordisk A/S
Bagsværd, Denmark, 15 July 2024 – On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16...
Novo Nordisk receives Complete Response Letter in the US for once-weekly basal insulin icodec
July 10, 2024 17:45 ET
|
Novo Nordisk A/S
Bagsværd, Denmark, 10 July 2024 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) covering the Biologics License Application for...
Novo Nordisk A/S - share repurchase programme
July 08, 2024 09:18 ET
|
Novo Nordisk A/S
Bagsværd, Denmark, 08 July 2024 – On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16...
Novo Nordisk A/S - share repurchase programme
July 01, 2024 09:19 ET
|
Novo Nordisk A/S
Bagsværd, Denmark, 01 July 2024 – On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16...
Novo Nordisk stops the ocedurenone CLARION-CKD trial and recognises impairment loss
June 26, 2024 10:50 ET
|
Novo Nordisk A/S
Bagsværd, Denmark, 26 June 2024 – Novo Nordisk today announced that the CLARION-CKD phase 3 trial failed to meet its primary endpoint and that it will recognise an impairment loss of around DKK 5.7...
Novo Nordisk announces 4.1 billion USD investment to expand US manufacturing capacity
June 24, 2024 14:16 ET
|
Novo Nordisk A/S
In 2024, Novo Nordisk plans to boost its current investments, aiming to allocate USD 6.8 billion towards production, a significant increase from the previous year's investment of USD 3.9 billion*. ...
Novo Nordisk A/S - share repurchase programme
June 24, 2024 08:55 ET
|
Novo Nordisk A/S
Bagsværd, Denmark, 24 June 2024 – On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16...
Novo Nordisk A/S: Mim8 demonstrated superior reductions in annualised bleeding rate (ABR) compared to on-demand and prior prophylaxis treatment in people with haemophilia A
June 23, 2024 01:01 ET
|
Novo Nordisk A/S
FRONTIER2 data presented at ISTH 2024 showed that up to 95% of people, who had no prior prophylaxis treatment, experienced zero treated bleeds while on Mim8 Bagsværd, Denmark, 23 June 2024 – Novo...